Cargando…

Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma

SIMPLE SUMMARY: Preclinical analyses identified APR-246 as a potent treatment option for neuroblastoma. However, a specific mode of action, sufficient biomarkers and promising combination partners are still missing. Here, we analyze the susceptibilities of different entities and relate them to gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Michael, Rösch, Lisa, Najafi, Sara, Gatzweiler, Charlotte, Ridinger, Johannes, Gerloff, Xenia F., Jones, David T. W., Baßler, Jochen, Kreth, Sina, Stainczyk, Sabine, Frese, Karen, Meder, Benjamin, Westermann, Frank, Milde, Till, Peterziel, Heike, Witt, Olaf, Oehme, Ina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431508/ https://www.ncbi.nlm.nih.gov/pubmed/34503286 http://dx.doi.org/10.3390/cancers13174476

Ejemplares similares

Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts
por: Wrobel, Jagoda K, et al.
Publicado: (2020)

Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma
por: Körholz, Katharina, et al.
Publicado: (2021)

Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models
por: Gatzweiler, Charlotte, et al.
Publicado: (2022)

ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein
por: Rösch, Lisa, et al.
Publicado: (2022)

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment
por: Shen, Jing, et al.
Publicado: (2018)

Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance
por: Ridinger, Johannes, et al.
Publicado: (2018)

Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
por: Vollmer, Johanna, et al.
Publicado: (2023)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021)

The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines
por: Kolbinger, Fiona R., et al.
Publicado: (2018)

MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma
por: Lodrini, Marco, et al.
Publicado: (2013)

LGG-16. NOVEL COMBINATION THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMA AND CHARACTERIZATION OF THE UNDERLYING CELL DEATH MECHANISMS
por: Zeiser, Constantia, et al.
Publicado: (2023)

Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation
por: Rettig, I, et al.
Publicado: (2015)

APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
por: Xie, Xuqin, et al.
Publicado: (2023)

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023)

LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics
por: Sigaud, Romain, et al.
Publicado: (2022)

Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance
por: Bingel, Corinna, et al.
Publicado: (2017)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity
por: Darwish, Salma, et al.
Publicado: (2022)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2018)

APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
por: Birsen, Rudy, et al.
Publicado: (2021)

Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome
por: Körber, Verena, et al.
Publicado: (2023)

An open-label phase I dose-finding study of APR-246 in hematological malignancies
por: Deneberg, S, et al.
Publicado: (2016)

Correction: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2019)

HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities
por: Koeneke, Emily, et al.
Publicado: (2015)

Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors
por: Morgen, Michael, et al.
Publicado: (2020)

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013)

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
por: Haffo, Lena, et al.
Publicado: (2018)

Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1(MET)/APR-246
por: Aberdam, Edith, et al.
Publicado: (2020)

Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation
por: Milne, Julia V., et al.
Publicado: (2021)

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
por: Park, H., et al.
Publicado: (2022)

MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
por: Alborzinia, Hamed, et al.
Publicado: (2022)

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
por: Bykov, Vladimir J. N., et al.
Publicado: (2016)

Piperlongumine and p53-Reactivator APR-246 Selectively Induce Cell Death in HNSCC by Targeting GSTP1
por: Hang, Wei, et al.
Publicado: (2018)

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
por: Synnott, Naoise C., et al.
Publicado: (2018)

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
por: Thole, Theresa M, et al.
Publicado: (2017)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, X, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_roohamte410ct29gv10oaesvqn